Dr. Dunleavy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Road
Washington, DC 20037Phone+1 240-271-3902
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
- University College of Dublin National Univ SOMClass of 1994
Certifications & Licensure
- DC State Medical License 2021 - 2027
- MD State Medical License 2021 - 2026
- NY State Medical License 2010 - 2026
- VA State Medical License 2024 - 2026
Clinical Trials
- HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Roles: Contact
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma.Coen J Lap, Kieron Dunleavy
Clinical Lymphoma, Myeloma & Leukemia. 2025-02-27 - Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai
Leukemia & Lymphoma. 2025-02-03 - Evolving molecular classification of aggressive B-cell lymphoma.Stefan K Alig, Björn Chapuy, Daisuke Ennishi, Kieron Dunleavy, Daniel J Hodson
Histopathology. 2025-01-01
Press Mentions
- DLBCL: Major New Treatment BreakthroughsMay 17th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: